What Does the Research Say?
SS-31 has a robust pipeline of human clinical data, unusual for a therapeutic peptide. Key findings include direct mitochondrial targeting - SS-31 concentrates 1,000-fold in mitochondria compared to cytoplasm, stabilization of cardiolipin structure improving electron transport chain efficiency, reduced mitochondrial reactive oxygen species (ROS) production, improved cardiac function in heart failure models, restored mitochondrial function in aging tissues, and Phase III clinical trials for Barth syndrome and heart failure in humans (Stealth BioTherapeutics).
For dogs, SS-31 is particularly interesting for age-related mitochondrial decline (the "energy crisis" of aging), cardiac support in dogs with heart disease (very common in certain breeds), and exercise intolerance and fatigue in senior dogs. The clinical trial infrastructure means more safety and efficacy data exists for SS-31 than for most experimental peptides.
Weight-Based Dosing Reference
⚠️ Important: Consult your veterinarian for dosing specific to your dog. This is reference information only.
| Size | Weight | Breeds |
|---|---|---|
| Small | Under 25 lbs | Chihuahua, Dachshund, Pomeranian |
| Medium | 25–60 lbs | Beagle, Border Collie, Cocker Spaniel |
| Large | 60–100 lbs | Labrador, Golden Retriever, German Shepherd |
| Giant | Over 100 lbs | Great Dane, Mastiff, Saint Bernard |
🩺 Administration: SS-31 is administered by subcutaneous injection. It is not available orally. As a clinical-stage pharmaceutical, it is available through research/compounding channels but not yet as an approved drug in any species. Veterinary use is experimental and should be supervised by a vet familiar with mitochondrial medicine. Dosing protocols are derived from clinical trial data and should be weight-adjusted for dogs.
Side Effects & Safety
SS-31 has shown good tolerability in Phase I-III human clinical trials, which is a higher bar of safety evidence than most peptides on this site. Reported side effects in trials include injection site reactions (most common), mild headache, and transient GI upset. No serious safety signals have emerged from clinical trial programs. Because it targets fundamental mitochondrial function, it is generally well-tolerated - it improves a process that is already happening rather than introducing a foreign signaling pathway.
⚠️ Tumor Caution: Peptides promoting tissue repair or growth could theoretically accelerate existing tumors. Vet screening recommended before starting, especially for seniors and cancer-prone breeds.
Where to Get SS-31 (Elamipretide) for Dogs
🏪 Integrative Peptides (Pettides)
Pet-specific oral supplements. US-made, ≥99% purity, vet-recommended.
Full Review →Related Conditions
FAQ
What does SS-31 do for dogs?
SS-31 targets mitochondria - the energy factories in every cell. By stabilizing the mitochondrial membrane, it improves energy production, reduces oxidative damage, and supports cardiac and overall cellular function. Most relevant for senior dogs and dogs with heart disease.
Is SS-31 FDA-approved?
Not yet, but it is in Phase III clinical trials for heart failure and Barth syndrome in humans - further along the regulatory path than most peptides. Veterinary use is experimental.
Can SS-31 help my dog with heart disease?
SS-31 has shown cardiac benefits in heart failure models by improving mitochondrial function in cardiac cells. It may be a supportive therapy for dogs with heart disease, but should only be used under veterinary cardiology supervision alongside standard cardiac medications.
Veterinary Disclaimer: Educational only. Consult a licensed vet before starting any supplement. Affiliate Disclosure